Precigen Management
Management criteria checks 2/4
Precigen's CEO is Helen Sabzevari, appointed in Jan 2020, has a tenure of 4.75 years. total yearly compensation is $3.72M, comprised of 26.9% salary and 73.1% bonuses, including company stock and options. directly owns 0.77% of the company’s shares, worth $1.87M. The average tenure of the management team and the board of directors is 4.8 years and 10.5 years respectively.
Key information
Helen Sabzevari
Chief executive officer
US$3.7m
Total compensation
CEO salary percentage | 26.9% |
CEO tenure | 4.8yrs |
CEO ownership | 0.8% |
Management average tenure | 4.8yrs |
Board average tenure | 10.5yrs |
Recent management updates
Recent updates
We're Keeping An Eye On Precigen's (NASDAQ:PGEN) Cash Burn Rate
Feb 28Precigen: RRP Targeting With AdenoVerse Technology Platform
Jan 20Will Precigen (NASDAQ:PGEN) Spend Its Cash Wisely?
Nov 04Is Precigen (NASDAQ:PGEN) Using Debt In A Risky Way?
Jul 18Things Look Grim For Precigen, Inc. (NASDAQ:PGEN) After Today's Downgrade
May 15Some Shareholders Feeling Restless Over Precigen, Inc.'s (NASDAQ:PGEN) P/S Ratio
Apr 18Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?
Nov 10Precigen names Rutul Shah as chief operating officer
Sep 21Circling Back On Precigen
Aug 23Is Precigen (NASDAQ:PGEN) Using Too Much Debt?
Aug 10Precigen Q2 2022 Earnings Preview
Aug 07Precigen to sell Trans Ova Genetics for $170M upfront
Jul 05Precigen, Inc. (NASDAQ:PGEN) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
May 12Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?
May 10The Prognosis On Precigen
Jan 05Is Precigen (NASDAQ:PGEN) Using Too Much Debt?
Dec 31CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Jun 30 2024 | n/a | n/a | -US$135m |
Mar 31 2024 | n/a | n/a | -US$97m |
Dec 31 2023 | US$4m | US$1m | -US$96m |
Sep 30 2023 | n/a | n/a | -US$85m |
Jun 30 2023 | n/a | n/a | -US$73m |
Mar 31 2023 | n/a | n/a | -US$79m |
Dec 31 2022 | US$3m | US$1m | -US$80m |
Sep 30 2022 | n/a | n/a | -US$84m |
Jun 30 2022 | n/a | n/a | -US$103m |
Mar 31 2022 | n/a | n/a | -US$108m |
Dec 31 2021 | US$3m | US$1m | -US$111m |
Sep 30 2021 | n/a | n/a | -US$124m |
Jun 30 2021 | n/a | n/a | -US$125m |
Mar 31 2021 | n/a | n/a | -US$110m |
Dec 31 2020 | US$20m | US$1m | -US$104m |
Sep 30 2020 | n/a | n/a | -US$100m |
Jun 30 2020 | n/a | n/a | -US$122m |
Mar 31 2020 | n/a | n/a | -US$138m |
Dec 31 2019 | US$1m | US$500k | -US$169m |
Sep 30 2019 | n/a | n/a | -US$373m |
Jun 30 2019 | n/a | n/a | -US$381m |
Mar 31 2019 | n/a | n/a | -US$414m |
Dec 31 2018 | US$3m | US$500k | -US$375m |
Compensation vs Market: Helen's total compensation ($USD3.72M) is above average for companies of similar size in the US market ($USD1.45M).
Compensation vs Earnings: Helen's compensation has increased whilst the company is unprofitable.
CEO
Helen Sabzevari (62 yo)
4.8yrs
Tenure
US$3,719,061
Compensation
Dr. Helen Sabzevari, Ph.D. MPH, served as Independent Director at Kinnate Biopharma Inc. from June 2021 to April 3, 2024. She has been President and Chief Executive Officer of Precigen, Inc (formerly Intre...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Executive Chairman | 16.7yrs | US$600.00k | 0.40% $ 964.3k | |
President | 4.8yrs | US$3.72m | 0.77% $ 1.9m | |
Chief Financial Officer | 3yrs | US$1.13m | 0.080% $ 193.3k | |
Chief Operating Officer | no data | US$1.04m | 0.073% $ 176.7k | |
Chief Legal Officer & Corporate Secretary | 13.8yrs | US$1.06m | 0.19% $ 453.4k | |
Senior Vice President of Intellectual Property Affairs | 10.2yrs | US$872.09k | 0.26% $ 626.1k | |
VP & Head of Investor Relations | 6.8yrs | no data | no data | |
VP & Head of Human Resources | no data | no data | no data | |
Senior VP & Head of Research | no data | no data | no data | |
Senior VP & Head of CMC | no data | no data | no data | |
Senior VP & Head of Clinical Operations and Regulatory Affairs | 1.3yrs | no data | no data | |
Chief Commercial Officer | less than a year | no data | no data |
4.8yrs
Average Tenure
62yo
Average Age
Experienced Management: PGEN's management team is considered experienced (4.8 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Executive Chairman | 16.7yrs | US$600.00k | 0.40% $ 964.3k | |
President | 4.3yrs | US$3.72m | 0.77% $ 1.9m | |
Independent Director | 12.9yrs | US$319.00k | 0.14% $ 331.5k | |
Independent Director | 8.3yrs | US$306.50k | 0.36% $ 867.7k | |
Independent Director | 16.7yrs | US$312.50k | 0.20% $ 480.2k | |
Lead Independent Director | 10.5yrs | US$312.50k | 0.16% $ 398.1k | |
Independent Director | 16.7yrs | US$300.00k | 0.36% $ 863.0k | |
Independent Director | less than a year | no data | 0.0061% $ 14.8k | |
Independent Director | 7.5yrs | US$306.50k | 0.16% $ 383.9k |
10.5yrs
Average Tenure
69yo
Average Age
Experienced Board: PGEN's board of directors are seasoned and experienced ( 10.5 years average tenure).